Covidien Reports Postive Data from DURABILITY II Study, Says Data Supports Treatment
October 14, 2013 at 16:21 PM EDT
Covidien (NYSE: COV ), a leading global provider of healthcare products, has released positive final results from its DURABILITY II study and promising preliminary data from its DEFINITIVE AR trial at the Vascular Interventional Advances (VIVA) 2013 conference in Las Vegas, NV. These studies demonstrate the safety and effectiveness of technologies used in
